

Review Article

Potential role of estrogen in the pathobiology and prevention of Alzheimer's disease

Whitney Wharton^{1,2}, Carey E. Gleason^{1,2}, Katelin R. Lorenze^{1,2}, Tamara S. Markgraf^{1,2}, Michele L. Ries^{1,2}, Cynthia M. Carlsson^{1,2}, Sanjay Asthana^{1,2}

¹Department of Medicine, University of Wisconsin, Madison, ²Geriatric, Research, Education and Clinical Center, William S. Middleton Memorial Veterans Hospital, Madison, WI

Received January 14, 2008; accepted January 16, 2009; available online January 20, 2009

Abstract: Over a decade of converging findings from clinical, observational and basic science research indicate that estrogen administration during the menopausal transition exerts beneficial effects on cognition and decreases a woman's risk of developing Alzheimer's disease (AD) later in life. This review article stresses the research focus of AD prevention, and introduces hormone therapy (HT) as a probable catalyst that may achieve this goal. Furthermore, this article outlines 3 mechanisms proposed to mediate estrogen's beneficial effects, discusses the controversy surrounding HT administration, and presents the most promising estrogen related research in AD prevention and treatment. Although controversial, cumulative evidence suggests that the potential of estrogen initiated during perimenopause to prevent AD needs to be systematically evaluated.

Key Words: Estrogen, estrogen therapy, hormone therapy, cognition, Alzheimer's disease, postmenopausal cognition, women's health initiative

Introduction to Alzheimer's disease and hormone therapy

Background

With the expected surge of the elderly population in the coming decades, the prevalence of Alzheimer's disease (AD) is projected to increase dramatically [1, 2]. These estimates emphasize the importance of early detection, intervention and ultimately prevention rather than treatment. A delay in the onset of disease by as few as five years is projected to have a substantial beneficial effect, reducing the prevalence of AD by 50% in one generation [1]. Basic science, observational, epidemiological and clinical research suggests that hormone therapy (HT) may prevent cognitive decline associated with AD in postmenopausal women up to 34% ([3] see Brann et al. [4] Miller et al. [5] Hogervorst et al. [6] Fillit [7] and Gleason et al. [8] for reviews). Multiple mechanisms have been posited to explain estrogen's protective effects

on AD. The current review will focus on the importance of AD prevention in terms of three of the most highly promising mechanisms, including neuromodulation, neuroprotection, and cerebrovascular regulation. Additionally, basic science, observational and clinical studies examining the relationship between HT administration and AD prevention will be discussed.

The main symptom of AD is episodic memory loss, with deficits in other cognitive domains, such as working memory and language, which usually appear later. At present, drugs designed to treat AD, are mainly cholinesterase inhibitors, which work by preventing synaptic breakdown of acetylcholine in the brain. However, cholinesterase inhibitors alleviate only some AD symptoms and a positive treatment response is seen in a considerably small subset of the affected population. While an ideal pharmacologic treatment for AD should be directed towards multiple pathophysiologic

Estrogen and Alzheimer's disease

mechanisms, have the potential to favorably alter disease neurobiology and be administered as early in the disease process as possible, the most promising defense against AD onset and progression is AD prevention.

Prevention vs. treatment

There is increasing evidence that the pathology of AD starts decades before the onset of the clinical symptoms. Once the symptoms of AD manifest, significant neuronal loss has already occurred and, as of now, disease progression cannot be reversed. As such, the ideal time for both early detection and intervention is at the beginning of the prodromal (and functionally "silent") period of neuropathologic change, rather than years later at the appearance of the dementia syndrome. Though research has yet to pinpoint exactly when neuropathologic changes begin, there is compelling evidence that the drastic drop in estrogen levels during the menopausal transition is closely linked to an increased risk of cognitive decline and subsequent AD in women. Thus, beginning a HT regimen during the menopausal transition is likely to delay the onset of AD, and could possibly prevent AD in a significant number of women.

Table 1 illustrates clinical studies investigating the cognitive actions of estrogen in healthy, postmenopausal women. For the most part, clinical data indicate cognitive benefits in women using HT. Such findings led to questions regarding HT's potential to reduce the risk of developing AD later in life. The results reported in **Table 1** suggest that the beneficial effects of estrogen play a role in AD prevention, because the studies were conducted in women without AD [9-11]. Retrospective and observational studies are also consistent with these positive outcomes, particularly in women who began HT during the menopausal transition [10, 12, 13]. The comparable benefit seen as a result of estrogen/HT suggest that for the most part, the data within the observational studies were derived from women with healthy neurological status [14].

Controversies in hormone therapy

Background

While the majority of research studies suggest that beginning a HT regimen during the menopausal transition is likely to delay and decrease the risk of developing AD later in life, the subject of HT administration remains controversial [15]. The source of much debate surrounding HT can be traced back to findings from the seminal Women's Health Initiative [16] (WHI) and its two ancillary studies, the WHI Memory Study [17] (WHIMS) and the WHI Study of Cognitive Aging [18] (WHISCA), which characterized the cognitive efficacy and adverse effect profile of conjugated equine estrogen (CEE) plus medroxyprogesterone acetate (MPA) in older postmenopausal women. The WHIMS found an increased risk for dementia in postmenopausal women aged 65 and older, treated with CEE and MPA, though prior and subsequent research consistently shows that HT improves cognition, likely via multiple neural mechanisms, and may reduce a woman's risk for dementia and [19-21]. The surprising findings from WHIMS indicated an increased risk of dementia and cognitive decline with prolonged administration of CEE [17, 18, 22-24], and prior findings from cohort studies were attributed to inherent flaws in epidemiological research, such as the 'healthy-user' bias. However, support for potential salutary effects of estrogen on cognition and risk for dementia continues to mount from observational (including WHIMS data) [25] as well as prospective cohort studies [3, 10, 26-34]. Some researchers have argued that the WHI was not a true primary prevention study, given the advanced age of participants and the likelihood that they were beyond the opportunity to 'prevent' disease [35]. Moreover, it is speculated that the type of estrogen employed in the WHI, opposed CEE, might underlie the increased risk for dementia and cerebrovascular changes [36].

HRT preparation

The WHI employed the most commonly used form of HT, oral Prempro® and Premarin®. Rather than mimicking premenopausal hormone profile or cycles, these hormones elevate steady-state levels of estrone and nine other estrogens [35, 37], and in the case of Prempro®, a synthetic form of progesterone, MPA. Prior to menopause, the predominant circulating estrogen is ovarian-produced estradiol, while after menopause the primary source of estradiol is peripheral conversion of

Estrogen and Alzheimer's disease

Table 1. Summary of Clinical Studies Examining the Cognitive Effects of HT

INVESTIGATOR(S)	OUTCOMES	
Caldwell & Watson	Improvement in learning and memory	Benefit
Rauramo et al.	No improvement on tests of memory or reaction time (RT)	No Benefit
Fedor-Freyburgh	Improvement on RT, visual attention, selective attention, & memory	Benefit
Sherwin	Treatment improved verbal memory & abstract verbal reasoning	Benefit
Sherwin & Phillips	Treatment improved verbal memory	Benefit
Phillips & Sherwin	Treatment improved verbal memory	Benefit
Rudolph et al.	Benefited subjective well-being & to a lesser extent conc. & atten	Benefit
Linzmayr et al.	Improved verbal & visual memory & information processing speed	Benefit
Saletu	Treatment benefited sleep and selected cognitive abilities	Benefit
Polo-Kantola et al. & Alhola et al.	No differences between treatment & placebo with 3 mo intervention. Follow-up 6 years later, still no difference	No Benefit
Hogervorst et al.	Trend for improved verbal memory on treatment	Benefit
Wolf et al.	No group differences but correlation between estrogen level & cognitive performance on verbal memory measures	Benefit
Duka et al.	Treatment improved memory & nonverbal reasoning	Benefit
Viscoli et al.	2 nd -ary prevention trial in women with recent history of stroke. Less decline over 3 years on MMSE for cognitively normal women on HT. But no benefit for entire group (when baseline MMSE not considered)	Benefit
Taxel et al.	Men on hormone suppression for prostate CA received E2 or placebo	No Benefit
Dunkin et al.	Only weak support for overall benefit of E2; but data suggest that women with increased lifetime exposure or recent exposure benefited	Benefit
Schiff et al.	12 wks of TX (cross-over design) improved RT, but no other ability	No Benefit
Almeida et al.	20 weeks of 2mg/day tx on cognition, mood and QOL questionnaires	No Benefit
Yaffe et al.	1 and 2 yrs of an "ultra low dose" (0.014 mg/d)	No Benefit
Dumas et al.	After 3 mos tx administered Scopolamine a cholinergic challenge Women on E2 do better on measures of atten, RT & speeded fx	Benefit
Krug et al.	3-day treatment resulting in E2 levels similar to mid-cycle premenopause resulted in improved performance on tests of prefrontal cortex executive function	Benefit
Hackman & Galbraith	Treatment improved score on memory test , using piperazine estrone sulfate	Benefit
Campbell & Whitehead	Improved memory with treatment	Benefit
Honjo et al.	Treatment group improved on screening tests for dementia	Benefit
Ditkoff et al.	No benefit on tests of learning, & auditory & visual atten (WAIS)	No Benefit
Janowsky et al.	No improvement on working memory with treatment	No Benefit
Binder et al.	No benefit with treatment on comprehensive battery of neuropsychological tests	No Benefit
Grady et al.	No benefit on cognitive tests for women with coronary heart disease	No Benefit
Woo et al.	Improved atten, delayed recall & score on global cognitive fx	Benefit
Shaywitz et al.	CEEs improved reading ability and verbal memory	Benefit
Pan et al.	Nonsignificant trend for benefit on global cognitive measures	Benefit
WHIMS	Decline on 3MSE & twice the risk for dementia with CEE	Harmful
WHISCA	Less decline on visual spatial construction & memory, but greater declines on learning & recall with opposed CEE	Benefit & Harm
Maki et al.	Borderline significance suggesting minimally worse verbal memory with CEE. (notably enrollment and study completion adversely affected by WHIM per study authors).	Harm
Vanhulle & Demol	Estriol had no effect on intell, atten & conc or speeded processing	No Benefit

Estrogen and Alzheimer's disease

androstenedione [38]. Estradiol is a very potent naturally occurring estrogen, while estrone and estriol are reported to have lower binding affinities, and thus may fail to induce the full array of neuronal changes induced by estradiol [38]. The dramatic decrease in circulating estradiol, and subsequent increase in gonadotropins may explain the increased risk for cardiac disease and osteoporosis, and possibly for dementia [39-41]. Thus, in order to enhance receptor-dependent cognitive actions of estrogen and to more closely mimic the premenopausal state, estradiol may be a more appropriate replacement strategy. This assertion is supported by **Table 1**, which shows that trials using estradiol preparations more often demonstrated cognitive benefits than did investigations utilizing a CEE.

Preliminary findings from recent studies suggest that, unlike oral conjugated estrogen, transdermal estradiol enhanced cognitive function for postmenopausal women with AD [15, 42]. This may be related to the absence of venous thromboembolic complications [43], and plasma markers of inflammation [44] associated with transdermal estrogen administration. Thus, it may be that not only is the form of HT significant, but the route of administration may be equally critical. Many in the scientific community agree that while the risk of dementia associated with the administration of Prempro® has been clarified for women over the age of 65, research regarding the use of other forms of HT for primary prevention of dementia is highly promising, particularly if estradiol is administered during the menopausal transition, before the period of AD associated neuropathologic change begins [45, 46].

Mechanisms mediating the estrogen – Alzheimer's disease relationship

Estrogen and neuromodulation

The Alzheimer's disease brain – estrogen receptors

Many of the structural and functional aspects of the AD brain are influenced by both endogenous and exogenous estrogen levels. Examination of the AD brain at autopsy reveals marked atrophy in the basal forebrain and mesial temporal structures (i.e. the amygdala, entorhinal cortex and particularly the hippocampus). There is a significant loss of

large pyramidal neurons but the primary sensory cortices are largely spared [47], and the amount of neuronal loss correlates well with functional dementia and cognitive test scores [48]. Moreover, the clinical symptomology corresponds closely to the regional progression of brain change over time (i.e. hippocampus and memory). Also, there is considerable synaptic loss in the association neocortex as compared to control brains. Therefore, AD manifests as selected neuronal loss and decreased synaptic connections in a temporally selective manner.

There is compelling scientific evidence indicating the neuromodulatory efficacy of estrogen and HT, which is directly relevant to AD neuropathology and prevention. Estrogen exerts its biological actions through estrogen receptors (ER) distributed selectively throughout the brain. Several of these brain regions, namely the hippocampus, mediate various cognitive functions including memory, and are selectively affected by AD pathology. These brain regions include the association cortices, midbrain, brainstem, basal forebrain, pituitary gland, hypothalamus, amygdala and particularly the hippocampus [49-53].

Estrogen's effects on brain regions important to memory

Estrogen has been shown to increase synaptic protein expression [54], synaptic structural plasticity [55] and density of pyramidal cells in the hippocampus [56, 57] via the activation of ER α and ER β expressed in the CA1 neuronal field [58-61] and prefrontal cortex [62]. Consistent with these structural changes, investigators report enhanced working memory performance as measured by the Morris water maze task within the time frame of estrogen-induced increases in hippocampal pyramidal cell density [63]. Additionally, estradiol has recently been shown to induce changes in the structural mechanics of cells via mRNA expression levels within the dorsal hippocampus, which could be conducive to promoting memory encoding and consolidation [64]. These results suggest that estrogen-dependent changes in the hippocampus are, at least in part, responsible for the hormonal effects on cognitive functions seen across the menopausal transition [65]. Thus, estrogen's salutary action on these brain regions is a highly promising mechanism in AD prevention.

Estrogen and Alzheimer's disease

Estrogen's interaction with neurotransmitter systems

In addition to estrogen's actions on specific brain regions involved in memory and vulnerable to AD, there is cumulative scientific evidence portraying the facilitative role of estrogen on various neurotransmitter systems (See van Amelsvoort et al. [66] and Yaffe [67] for reviews). Among others, neurotransmitters influenced by estrogen include acetylcholine, serotonin, and the catecholamines (dopamine, epinephrine, and norepinephrine), all of which have been implicated in the modulation of the cognitive processes specifically affected by the pathology of AD [68]. Of particular importance is the cholinergic system, a system integrally involved in several cognitive processes, including attention, learning, memory, and arousal. In patients with AD, notable and early deficits are found in the basal forebrain, the primary seat of cholinergic activity. As noted earlier, the current FDA approved treatments for the disease consist mainly of medications designed to enhance cholinergic function. Importantly, basic research suggests that estrogen facilitates the actions of the cholinergic system [69-75]. Thus, the precipitous drop in estrogen during menopause could contribute to cognitive dysfunction based on the deregulation of acetylcholine, suggesting that HT administration during this important period may combat cognitive decline and later AD. Estrogen appears to also influence neuronal communication through the serotonergic (5-HT) [70, 76-78], dopaminergic [79-82], noradrenergic and adrenergic [83-86] neurotransmitter systems. Thus, estrogen appears to have multiple and complex effects via neuromodulation, and therefore likely serves as a probable contender in regard to AD prevention.

Estrogen and neuroprotection

Neuroprotection is the process of protecting the brain from neuronal injury or the clinically relevant delaying of disease progression [87]. Here, we discuss some of the neuroprotective effects of estrogen, which have direct implications for AD prevention. Basic science has established that estrogen, particularly 17 β -estradiol, protects the brain from various types of insults and injury, including ischemic stroke [88, 89], beta-amyloid (A β) neurotoxicity [90, 91] oxidative damage [92] and apoptosis

[80]. Estrogen has also been shown to enhance recovery from traumatic brain injury following cerebral ischemia [93] and to reduce brain inflammation, [94] especially inflammation due to A β [95]. Additionally, a recent study by Brinton confirmed that estradiol regulates mitochondrial function and enhances aerobic glycolysis [14], which have been shown to be precipitating factors in age-associated neurodegenerative diseases such as AD [96, 97].

Estrogen's effect on beta amyloid (A β)

Plaques are one of two primary types of pathology associated with AD. The neuritic plaques are extracellular protein aggregates of A β , decorated with complement components, lipoproteins, and a variety of acute phase proteins which are surrounded by degenerating nerve endings and activated microglia and astrocytes [98]. A β deposition is a hallmark of AD, and used as a biomarker of AD risk and development. Many studies suggest that the estrogenic component of HT is responsible for reducing A β levels [99]. Thus, A β reduction is a principal biomarker by which many basic scientists gauge the beneficial effects of HT. As mentioned earlier, estrogen has been shown to reduce inflammatory responses to A β in humans. In addition, studies show that estrogen improves CSF clearance of insoluble A β , while increasing amounts of non-toxic soluble A β [35] (See **Figure 1**). Also, in vitro findings from cultured neurons suggest that estrogen may prevent AD pathogenesis by protecting against A β -mediated neurotoxicity, and enhancing A β clearance [90]. Based on the widely acknowledged relationship between estrogen, A β and AD, there is little doubt that the postmenopausal decline in estrogen levels contribute to detrimental cognitive effects and a higher risk profile for AD development. Hence, prolonging premenopausal estradiol levels could serve to delay, or perhaps prevent AD by preventing A β neurotoxicity.

Estrogen and apolipoprotein E (ApoE)

The E4 allele of the apolipoprotein E (ApoE) gene is a well known genetic risk factor for AD. The influence of estrogen on ApoE expression is a relatively new area, and while some studies have found that estrogen exerts beneficial actions on ApoE upregulation and




Figure 1. Illustration of amyloid precursor protein (APP) cleaving pathway. Estrogen reduces cleavage at β secretase and γ secretase, shown in the right arm of the figure, which reduces accumulation of toxic β amyloid plaques.

expression, the true relationship remains unclear [100]. First, some research suggests an upregulation of ApoE with estrogen

administration [101-103]. However, a related line of research reports that only the E4 carriers experience the beneficial cognitive

Estrogen and Alzheimer's disease

effects of HT [19, 104], while others have failed to find a statistically significant interaction between HT's neuroprotective effects and ApoE status [10]. Wang et al. has reported that ER α increases and ER β decreases ApoE expression in the hippocampus in rats [105]. They have argued that the interaction of E4 allele status and estrogen receptor type may partially explain the complex results in human clinical trials of HT on cognitive function. Other studies have reported that HT increases the risk of AD in those with the E4 allele and to decrease risk in those with the E2 or E3 allele [106, 107]. Wang suggested that an increase of ER α combined with HT will increase ApoE which would selectively increase the risk of cognitive impairment in ApoE 4 positive individuals, in a heterogeneous population in a large clinical trial [105]. Indeed, research investigators examining the effects of estrogen on AD treatment and prevention should consider ApoE4 status and the potential impact this AD risk factor may have on the results of estrogen studies.

Estrogen's Neurovascular Effects

One of the most promising areas of research linking HT administration to AD prevention involves estrogen's salutary effects on cerebral blood flow (CBF). Estrogen's influence on CBF can in part be attributed to the hormone's multiple and well-documented actions on cerebral vasculature. These effects have been shown to be mediated through ER α and ER β [108-110] as well as numerous non-genomic influences on signaling pathways, induced by activation of membrane receptors [111-114] and alterations of membrane ion channels [115-117]. Thus, estrogen imparts both rapid and delayed effects upon cerebral vessels [113]. One means through which estrogen increases CBF is through its effects on dilation of blood vessels via improved vascular reactivity [118, 119] and endothelial function [120-124]. Both smooth muscle and endothelial layer cerebral vessels express estrogen receptors [118]. Cerebral vascular dilation related to improved endothelial function appears to result from estrogen's influences on vasoregulators, such as nitric oxide (NO) and prostanoids. For example, estrogen has extensive effects upon eNOS and nNOS regulation and activity [125-133], influencing eNOS production of NO through

various processes, including sensitizing eNOS to calcium activation through phosphorylation [114] and increased calmodulin production [129], and decreasing inhibition of eNOS by the caveolin-1 protein [113, 129]. Of particular relevance to the current review, estrogen effects on NO production have been found to occur in the hippocampus [134] and forebrain areas [135], primary regions showing neurodegeneration in AD.

Estrogen also increases vasodilation through its effects on prostanoids (e.g., prostacyclin (PGI₂)). The influence of PGI₂ upon vasculature appears to occur through increased eNOS activity, possibly mediated by the enzyme cyclooxygenase-1 [136-138] (COX-1). Additional mechanisms through which estrogen optimizes endothelium vasodilatory responses include interactions with vasoreactive substances other than NO [139, 140] and changes in smooth muscle responses [116, 141]. Also, estrogen has been shown to favorably influence several other aspects downstream of cerebral perfusion, including improved mitochondrial energy metabolism [142-145] protection from by-products mitochondrial energy metabolism (reactive oxygen species (ROS) and peroxides) [143], and reduced thrombotic [146] and endothelial inflammatory activity [147-150]. Moreover, there appears to be both rapid [111, 113, 151-157] and long-term [158-160] effects upon cerebral vascular response. While it remains to be proven, the above data along with new evidence of HT effects in ApoE E4 carriers [161, 162], it is plausible that HT-related improvements in CBF may offer some protection or delay the progression of AD in women if administered during the menopausal transition.

Estrogen's Effects on Cognition

In addition to the neuromodulatory, neuroprotective and the cerebrovascular effects of estrogen on AD prevention, further support can be found within the cognitive neuropsychology literature. Of note, estradiol formulations appear to provide a more promising outcome with regards to cognitive benefits, particularly in older populations. For instance, bioavailable estradiol has been found to be more predictive of positive cognitive changes over time than estrone [6]. There is well-documented and compelling evidence to support estrogen's neurobiological

Estrogen and Alzheimer's disease

role in cognitive processes. (See McEwen [163] for review.) Specifically, estradiol has been linked to improved performance on tasks of attention, visuospatial ability, learning and memory, and particularly verbal ability. The recognition of estrogen's numerous neurotrophic and neuroprotective actions suggests a possible deleterious effect of chronic estrogen deprivation, both in healthy aging and disease processes. The cognitive data also supports the theory that the dramatic decrease in estrogen levels occurring at menopause could result in neuronal dysregulation and loss of protective actions, and perhaps account for women's increased risk for AD [39-41]. In sum, a review of the scientific literature indicates that estrogen has cognitively beneficial properties and administration of HT during the menopausal transition will likely reduce the cognitive decline associated with AD symptomology.

Research Investigating the Relationship between Estrogen and Alzheimer's Disease

Estrogen and AD Prevention

Research investigating the effects of estrogen on AD has been comprehensive and interdisciplinary. The large amount of research has spanned from the basic mechanistic effects of estrogen on AD risk and prevention to double-blind, randomized, placebo controlled studies investigating the effects of HT on participants already afflicted with AD. With the exception of a few studies, namely the WHI and the WHIMS, most research supports a beneficial effect of estrogen on cognition and subsequent AD prevention. Although the expanse of literature is beyond the scope of this review, we discuss here, some of the most important and most recent scientific research studies investigating the effects of estrogen on AD.

Estrogen in Basic Science Models of AD

Basic science analyses examining the neuromodulatory and neuroprotective effects of estrogen were essential to the development of an estrogen-mediated model of AD prevention [14]. Like epidemiological studies, evidence from in vitro and in vivo animal studies supporting estrogen's favorable neuroprotective effects have generally been conducted using estradiol formulations, as opposed to estrone. Overall, mouse models

have shown that estradiol enhances neuroplasticity, induces anti-inflammatory and cytoprotective effects, reduces A β plaques from its precursor protein, and modulates glucose metabolism. In one well designed mouse model of AD, investigators found that estrogen-deficient mice exhibited greatly increased A β deposition and production [99]. In the same study, investigators measured estradiol levels in the brain tissue of women with and without AD. Results showed that AD patients had significantly reduced estradiol levels in the frontal cortex, a region characteristically affected in AD [99]. In another well conducted, recent line of research, estradiol was administered intraperitoneally in rats immediately following training on the Morris water maze task. Results showed that estradiol enhanced both spatial reference memory [164, 165] and novel object recognition memory [166] in mice and rats. Finally, a handful of researchers have reported that estrogen exerts neuroprotective actions via preventing the phosphorylation of tau, a microtubule-associated protein closely associated with AD. Specifically, 17 β estradiol can reportedly prevent neural tau hyperphosphorylation at multiple AD-related sites and also attenuate the forskolin-induced elevation of cAMP and activation of PKA [167]. These findings, along with the results of similar basic models of AD, provide evidence that estrogen is a viable option for prevention of AD in postmenopausal women.

Observational Studies in Healthy Participants

While there is an abundance of observational research investigating the effect of HT on AD, evidence from two large observational studies [161, 162] provide the most direct evidence to date that HT can modify biomarkers of early disease related changes. Investigators found a neuroprotective effect of estradiol in a sample of women 'at risk' for developing AD based on the ApoE E4 genotype. Results indicated that estradiol therapy protected the 'at risk' women from AD associated changes, including hippocampal atrophy and diminished hippocampal neuronal metabolism volumes [161, 162]. Importantly, the neuroprotective effect was limited to neurobiology, as no difference in cognitive performance was detected between HT users and non-users. Of note, while participants in this sample were considered 'at risk,' they were not exhibiting

AD symptoms and had not been diagnosed, so deficits in cognition would not be expected. This study not only lends further support to the growing body of research showing a beneficial effect of estradiol in AD, but it also brings AD prevention and neuroprotection to the forefront. These promising findings offer the most direct link between HT usage and protection from early AD associated brain changes.

Estrogen Studies in Women with AD

While the focus of this review is the prevention of AD, it is worth mentioning that some clinical research has reported a favorable effect of HT administration in patients after a diagnosis of AD has been made. We discuss these studies because they lend further credence to estrogen's salutary properties in regard to AD specifically. Thus far, three clinical studies have supported a cognitive benefit in women with AD [15, 168, 169]. An early, double-blind, placebo-controlled study of 14 women with AD (aged 83.7 ± 4.5 y; mean \pm SD) suggested that CEE improved performance on the MMSE and the Hasegawa Dementia Scale (HDS-R). The seven women receiving 1.25 mg CEE showed significant memory score improvements in the MMSE after 3 weeks, while the placebo group did not display any significant change in the MMSE or HDS-R score.

Asthana et al. conducted a placebo-controlled, double-blind, parallel-group clinical study to evaluate the cognitive and neuroendocrine response to transdermal 17 β -estradiol in women with AD [168]. The treatment group exhibited improved attention, and verbal memory. Moreover, scores were directly correlated with plasma concentrations of estradiol. In a follow-up study, Asthana et al. reported that treatment with a high dose (0.10 mg per day) of 17 β -estradiol further enhanced cognitive task performance on tests of attention, verbal memory, visual memory and semantic memory in women with AD. Findings were replicated in a meta-analysis [15] and are consistent with those reported in several uncontrolled estradiol studies. These results provide evidence of a beneficial effect of estrogen on cognition in postmenopausal women with AD, and lend further support to HT prevention models of AD.

AD Risk Factors and Research

Although the current review has only skimmed the surface of the estrogen / AD relationship, it is clear that multiple factors warrant consideration when undertaking a project such as those described here. Several potentially mediating variables related to both AD and HT may clarify conflicting findings surrounding estrogen / AD research. In regard to AD prevention, very few studies have accounted for the multiple stages of AD pathology and ApoE status. Additionally, no data exists on women with other types of dementia (e.g. vascular dementia), or age of dementia onset (e.g. early AD). In fact, age in general is another variable that could potentially confound the effects of an investigation examining the effects of HT on AD prevention. In regard to HT, the differential effects of various hormone preparations and doses, as well as the effect of concomitant progestin therapy, hysterectomy status, prior history of HT exposure should be controlled. In addition, HT initiated during the menopausal transition (the 'critical period' hypothesis) has been associated with beneficial effects on AD biomarkers. Thus, it is crucial to initiate HT several years before the onset of AD cognitive symptoms in order to evaluate the full neuroprotective potential of estrogen.

Future Directions

While decades of basic science investigation of estrogen's actions in the brain and subsequent observational and clinical trials continue to confirm the benefit of estrogen based therapies on cognition, future research investigating the potential salutary effect of estrogen for AD prevention is essential. The prevalence of AD will continue to grow with the increase in the average lifespan in industrialized countries. Sixty-eight percent of individuals diagnosed with AD are women. The same 68% of women comprises roughly 5–10% of our population, and this statistic increases dramatically with age [170, 171]. Based on the aforementioned results, it is likely that a large scale, longitudinal, cyclical, HT study with transdermal estradiol would offer much needed information to the field of AD and hormone therapy research. The KEEPS (Kronos Early Estrogen Prevention Study) and the KEEPS Cognitive and Affective Study (KEEPS C/A) are currently underway and are positioned to address such issues. In

Estrogen and Alzheimer's disease

conclusion, we believe that the KEEPS and KEEPS C/A studies will provide much needed answers regarding the use of estrogen during the menopause and postmenopausal periods for the prevention of AD.

Acknowledgements

This research was conducted with the help of the Section of Geriatrics and Gerontology, Department of Medicine at the University of Wisconsin, Madison and the Geriatric Research, Education and Clinical Center (GRECC), William S. Middleton Memorial Veterans Hospital. This research was supported by NIH grants AG029624, K07AG021582, K23AG024302 and K23AG026752. VA manuscript number 2008-31.

Please address correspondences to: Whitney Wharton, PhD, University of Wisconsin School of Medicine and Public Health, William S. Middleton VA Hospital, 2500 Overlook Terrace, GRECC 11G Madison WI 53705, Tel: (608) 256-1901, ext. 11516, Email: wwharto@medicine.wisc.edu

References

- [1] Jorm AF, Dear KB and Burgess NM. Projections of future numbers of dementia cases in Australia with and without prevention. *Aust N Z J Psychiatry* 2005; 39: 959-963.
- [2] Hebert LE, Scherr PA, Bienias JL, Bennett DA and Evans DA. Alzheimer disease in the US population: prevalence estimates using the 2000 census. *Arch Neurol* 2003; 60: 1119-1122.
- [3] LeBlanc ES, Janowsky J, Chan BK and Nelson HD. Hormone replacement therapy and cognition: systematic review and meta-analysis. *Jama* 2001; 285: 1489-1499.
- [4] Brann DW, Dhandapani K, Wakade C, Mahesh VB and Khan MM. Neurotrophic and neuroprotective actions of estrogen: basic mechanisms and clinical implications. *Steroids* 2007; 72: 381-405.
- [5] Miller MM, Monjan AA and Buckholtz NS. Estrogen replacement therapy for the potential treatment or prevention of Alzheimer's disease. *Ann N Y Acad Sci* 2001; 949: 223-234.
- [6] Hogervorst E, Williams J, Budge M, Riedel W and Jolles J. The nature of the effect of female gonadal hormone replacement therapy on cognitive function in post-menopausal women: a meta-analysis. *Neuroscience* 2000; 101: 485-512.
- [7] Fillit HM. The role of hormone replacement therapy in the prevention of Alzheimer disease. *Arch Intern Med* 2002; 162: 1934-1942.
- [8] Gleason CE, Cholerton B, Carlsson CM, Johnson SC and Asthana S. Neuroprotective effects of female sex steroids in humans: current controversies and future directions. *Cell Mol Life Sci* 2005; 62: 299-312.
- [9] Nilsen J and Brinton RD. Impact of progestins on estrogen-induced neuroprotection: synergy by progesterone and 19-norprogesterone and antagonism by medroxyprogesterone acetate. *Endocrinology* 2002; 143: 205-212.
- [10] Zandi PP, Carlson MC, Plassman BL, Welsh-Bohmer KA, Mayer LS, Steffens DC and Breitner JC. Hormone replacement therapy and incidence of Alzheimer disease in older women: the Cache County Study. *Jama* 2002; 288: 2123-2129.
- [11] Resnick SM and Henderson VW. Hormone therapy and risk of Alzheimer disease: a critical time. *Jama* 2002; 288: 2170-2172.
- [12] Brinton RD. Investigative models for determining hormone therapy-induced outcomes in brain: evidence in support of a healthy cell bias of estrogen action. *Ann N Y Acad Sci* 2005; 1052: 57-74.
- [13] Yaffe K, Sawaya G, Lieberburg I and Grady D. Estrogen therapy in postmenopausal women: Effects on cognitive function and dementia. *JAMA* 1998; 279: 688-695.
- [14] Brinton RD. Estrogen regulation of glucose metabolism and mitochondrial function: therapeutic implications for prevention of Alzheimer's disease. *Adv Drug Deliv Rev* 2008; 60: 1504-1511.
- [15] Asthana S, Baker LD, Craft S, Stanczyk FZ, Veith RC, Raskind MA and Plymate SR. High-dose estradiol improves cognition for women with AD: results of a randomized study. *Neurology* 2001; 57: 605-612.
- [16] Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stefanick ML, Jackson RD, Beresford SA, Howard BV, Johnson KC, Kotchen JM and Ockene J. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. *Jama* 2002; 288: 321-333.
- [17] Espeland MA, Rapp SR, Shumaker SA, Brunner R, Manson JE, Sherwin BB, Hsia J, Margolis KL, Hogan PE, Wallace R, Dailey M, Freeman R and Hays J. Conjugated equine estrogens and global cognitive function in postmenopausal women: Women's Health Initiative Memory Study. *Jama* 2004; 291: 2959-2968.
- [18] Resnick SM, Maki PM, Rapp SR, Espeland MA, Brunner R, Coker LH, Granek IA, Hogan P, Ockene JK and Shumaker SA. Effects of combination estrogen plus progestin hormone treatment on cognition and affect. *J Clin Endocrinol Metab* 2006; 91: 1802-1810.
- [19] Tang MX, Jacobs D, Stern Y, Marder K, Schofield P, Gurland B, Andrews H and Mayeux R. Effect of oestrogen during menopause on risk and age at onset of Alzheimer's disease.

Estrogen and Alzheimer's disease

- Lancet 1996; 348: 429-432.
- [20] Henderson V, Paganini-Hill A, Emanuel C, Dunn M and Buckwalter J. Estrogen replacement therapy in older women. Comparisons between Alzheimer's disease cases and nondemented control subjects. *Arch Neurol* 1994; 51: 896-900.
- [21] Kawas C, Resnick S, Morrison A, Brookmeyer R, Corrada M, Zonderman A, Bacal C, Lingle DD and Metter E. A prospective study of estrogen replacement therapy and the risk of developing Alzheimer's disease: the Baltimore Longitudinal Study of Aging. *Neurology* 1997; 48: 1517-1521.
- [22] Shumaker SA, Legault C, Kuller L, Rapp SR, Thal L, Lane DS, Fillit H, Stefanick ML, Hendrix SL, Lewis CE, Masaki K and Coker LH. Conjugated equine estrogens and incidence of probable dementia and mild cognitive impairment in postmenopausal women: Women's Health Initiative Memory Study. *Jama* 2004; 291: 2947-2958.
- [23] Shumaker SA, Legault C, Rapp SR, Thal L, Wallace RB, Ockene JK, Hendrix SL, Jones BN, 3rd, Assaf AR, Jackson RD, Kotchen JM, Wassertheil-Smoller S and Wactawski-Wende J. Estrogen plus progestin and the incidence of dementia and mild cognitive impairment in postmenopausal women: the Women's Health Initiative Memory Study: a randomized controlled trial. *Jama* 2003; 289: 2651-2662.
- [24] Rapp SR, Espeland MA, Shumaker SA, Henderson VW, Brunner RL, Manson JE, Gass ML, Stefanick ML, Lane DS, Hays J, Johnson KC, Coker LH, Dailey M and Bowen D. Effect of estrogen plus progestin on global cognitive function in postmenopausal women: the Women's Health Initiative Memory Study: a randomized controlled trial. *Jama* 2003; 289: 2663-2672.
- [25] Henderson, V. W., Espeland, M. A., Hogan, P. E., Rapp, S. R., Stefanick, M. L., Wactawski-Wende, J., Johnson, K. C., Wassertheil-Smoller, S., Freeman, R., & Curb, D. (2007) in American Academy of Neurology Annual Meeting (Boston, MA).
- [26] Krug R, Born J and Rasch B. A 3-day estrogen treatment improves prefrontal cortex-dependent cognitive function in postmenopausal women. *Psychoneuroendocrinology* 2006; 31: 965-975.
- [27] Keenan PA, Ezzat WH, Ginsburg K and Moore GJ. Prefrontal cortex as the site of estrogen's effect on cognition. *Psychoneuroendocrinology* 2001; 26: 577-590.
- [28] Gleason CE, Schmitz TW, Hess T, Kosciak RL, Trivedi MA, Ries ML, Carlsson CM, Sager MA, Asthana S and Johnson SC. Hormone effects on fMRI and cognitive measures of encoding: importance of hormone preparation. *Neurology* 2006; 67: 2039-2041.
- [29] Lokken KL and Ferraro FR. The relationship between menopausal status, phase of menstrual cycle, and replacement estrogen on cognition in healthy women without dementia. *J Psychol* 2006; 140: 533-547.
- [30] Stephens C, Bristow V and Pachana NA. HRT and everyday memory at menopause: a comparison of two samples of mid-aged women. *Women Health* 2006; 43: 37-57.
- [31] Yonker JE, Adolfsen R, Eriksson E, Hellstrand M, Nilsson LG and Herlitz A. Verified hormone therapy improves episodic memory performance in healthy postmenopausal women. *Neuropsychol Dev Cogn B Aging Neuropsychol Cogn* 2006; 13: 291-307.
- [32] Maki PM, Zonderman AB and Resnick SM. Enhanced verbal memory in nondemented elderly women receiving hormone-replacement therapy. *Am J Psychiatry* 2001; 158: 227-233.
- [33] Smith YR, Giordani B, Lajiness-O'Neill R and Zubieta JK. Long-term estrogen replacement is associated with improved nonverbal memory and attentional measures in postmenopausal women. *Fertil Steril* 2001; 76: 1101-1107.
- [34] Ghidoni R, Boccardi M, Benussi L, Testa C, Villa A, Pievani M, Gigola L, Sabattoli F, Barbiero L, Frisoni GB and Binetti G. Effects of estrogens on cognition and brain morphology: involvement of the cerebellum. *Maturitas* 2006; 54: 222-228.
- [35] Bhavnani BR. Estrogens and menopause: pharmacology of conjugated equine estrogens and their potential role in the prevention of neurodegenerative diseases such as Alzheimer's. *J Steroid Biochem Mol Biol* 2003; 85: 473-482.
- [36] Yaffe K. Hormone therapy and the brain: Deja vu all over again. *JAMA* 2003; 289: 2717-2719.
- [37] Bhavnani BR, Nisker JA, Martin J, Aletubi F, Watson L and Milne JK. Comparison of pharmacokinetics of a conjugated equine estrogen preparation (premarin) and a synthetic mixture of estrogens (C.E.S.) in postmenopausal women. *J Soc Gynecol Investig* 2000; 7: 175-183.
- [38] Levrant S and Barnes R. Pharmacology of Estrogens. In: Lobo R, editors. *Treatment of the Postmenopausal Women: Basic and Clinical Aspects*. New York: Raven Press, Ltd.; 1994. p. 57-68.
- [39] Gao S, Hendrie HC, Hall KS and Hui S. The relationships between age, sex, and the incidence of dementia and Alzheimer disease: a meta-analysis. *Arch Gen Psychiatry* 1998; 55: 809-815.
- [40] Ott A, Breteler MM, van Harskamp F, Stijnen T and Hofman A. Incidence and risk of dementia. The Rotterdam Study. *Am J Epidemiol* 1998; 147: 574-580.
- [41] Andersen K, Launer LJ, Dewey ME, Letenneur L, Ott A, Copeland JR, Dartigues JF, Kragh-Sorensen P, Baldereschi M, Brayne C, Lobo A, Martinez-Lage JM, Stijnen T and Hofman A. Gender differences in the incidence of AD and

Estrogen and Alzheimer's disease

- vascular dementia: The EURODEM Studies. EURODEM Incidence Research Group. *Neurology* 1999; 53: 1992-1997.
- [42] Asthana S, Craft S, Baker LD, Raskind MA, Birnbaum RS, Lofgreen CP, Veith RC and Plymate SR. Cognitive and neuroendocrine response to transdermal estrogen in postmenopausal women with Alzheimer's disease: results of a placebo-controlled, double-blind, pilot study. *Psychoneuroendocrinology* 1999; 24: 657-677.
- [43] Scarabin P, Oger E, Plu-Bureau G and group obotEaTEs. Differential association of oral and transdermal oestrogen replacement therapy with venous thromboembolism risk. *Lancet* 2003; 362: 428-432.
- [44] Vongpatanasin W, Tuncel M, Wang Z, Arbique D, Mehrad B and Jialal I. Differential effects of oral versus transdermal estrogen replacement therapy on c-reactive protein in postmenopausal women. *J Am Coll Cardiol* 2003; 41: 1358-1363.
- [45] Manson JE, Bassuk SS, Harman SM, Brinton EA, Cedars MI, Lobo R, Merriam GR, Miller VM, Naftolin F and Santoro N. Postmenopausal hormone therapy: new questions and the case for new clinical trials. *Menopause* 2006; 13: 139-147.
- [46] Wickelgren I. Estrogen research. Brain researchers try to salvage estrogen treatments. *Science* 2003; 302: 1138-1139.
- [47] Rogers J and Morrison JH. Quantitative morphology and regional and laminar distributions of senile plaques in Alzheimer's disease. *J Neurosci* 1985; 5: 2801-2808.
- [48] Blessed G, Tomlinson BE and Roth M. The association between quantitative measures of dementia and of senile change in the cerebral grey matter of elderly subjects. *Br J Psychiatry* 1968; 114: 797-811.
- [49] Toran-Allerand CD, Miranda RC, Bentham WD, Sohrabji F, Brown TJ, Hochberg RB and MacLusky NJ. Estrogen receptors colocalize with low-affinity nerve growth factor receptors in cholinergic neurons of the basal forebrain. *Proc Natl Acad Sci U S A* 1992; 89: 4668-4672.
- [50] Shughrue PJ and Merchenthaler I. Evidence for novel estrogen binding sites in the rat hippocampus. *Neuroscience* 2000; 99: 605-612.
- [51] Shughrue PJ, Scrimo PJ and Merchenthaler I. Estrogen binding and estrogen receptor characterization (ERalpha and ERbeta) in the cholinergic neurons of the rat basal forebrain. *Neuroscience* 2000; 96: 41-49.
- [52] Shughrue PJ and Merchenthaler I. Estrogen is more than just a "sex hormone": novel sites for estrogen action in the hippocampus and cerebral cortex. *Front Neuroendocrinol* 2000; 21: 95-101.
- [53] Shughrue PJ and Merchenthaler I. Distribution of estrogen receptor beta immunoreactivity in the rat central nervous system. *J Comp Neurol* 2001; 436: 64-81.
- [54] Stone D, Rozovsky I, Morgan T, Anderson C and Finch C. Increased synaptic sprouting in response to estrogen via an apolipoprotein E-dependent mechanism: implications for Alzheimer's disease. *J Neurosci* 1998; 18(9): 3180-3185.
- [55] Li C, Brake WG, Romeo RD, Dunlop JC, Gordon M, Buzescu R, Magarinos AM, Allen PB, Greengard P, Luine V and McEwen BS. Estrogen alters hippocampal dendritic spine shape and enhances synaptic protein immunoreactivity and spatial memory in female mice. *Proc Natl Acad Sci U S A* 2004; 101: 2185-2190.
- [56] McEwen BS and Woolley CS. Estradiol and progesterone regulate neuronal structure and synaptic connectivity in adult as well as developing brain. *Exp Gerontol* 1994; 29: 431-436.
- [57] Woolley CS and McEwen BS. Estradiol mediates fluctuation in hippocampal synapse density during the estrous cycle in the adult rat. *J Neurosci* 1992; 12: 2549-2554.
- [58] Hao J, Janssen WG, Tang Y, Roberts JA, McKay H, Lasley B, Allen PB, Greengard P, Rapp PR, Kordower JH, Hof PR and Morrison JH. Estrogen increases the number of spinophilin-immunoreactive spines in the hippocampus of young and aged female rhesus monkeys. *J Comp Neurol* 2003; 465: 540-550.
- [59] Sakamoto H, Mezaki Y, Shikimi H, Ukena K and Tsutsui K. Dendritic growth and spine formation in response to estrogen in the developing Purkinje cell. *Endocrinology* 2003; 144: 4466-4477.
- [60] Znamensky V, Akama KT, McEwen BS and Milner TA. Estrogen levels regulate the subcellular distribution of phosphorylated Akt in hippocampal CA1 dendrites. *J Neurosci* 2003; 23: 2340-2347.
- [61] Rune GM, Wehrenberg U, Prange-Kiel J, Zhou L, Adelman G and Frotscher M. Estrogen up-regulates estrogen receptor alpha and synaptophysin in slice cultures of rat hippocampus. *Neuroscience* 2002; 113: 167-175.
- [62] Tang Y, Janssen WG, Hao J, Roberts JA, McKay H, Lasley B, Allen PB, Greengard P, Rapp PR, Kordower JH, Hof PR and Morrison JH. Estrogen replacement increases spinophilin-immunoreactive spine number in the prefrontal cortex of female rhesus monkeys. *Cereb Cortex* 2004; 14: 215-223.
- [63] Sandstrom NJ and Williams CL. Memory retention is modulated by acute estradiol and progesterone replacement. *Behav Neurosci* 2001; 115: 384-393.
- [64] Pechenino AS and Frick KM. The effects of acute 17beta-estradiol treatment on gene expression in the young female mouse

Estrogen and Alzheimer's disease

- hippocampus. *Neurobiol Learn Mem* 2008;
- [65] Takuma K, Matsuo A, Himeno Y, Hoshina Y, Ohno Y, Funatsu Y, Arai S, Kamei H, Mizoguchi H, Nagai T, Koike K, Inoue M and Yamada K. 17beta-estradiol attenuates hippocampal neuronal loss and cognitive dysfunction induced by chronic restraint stress in ovariectomized rats. *Neuroscience* 2007; 146: 60-68.
- [66] van Amelsvoort T, Compton J and Murphy D. In vivo assessment of the effects of estrogen on human brain. *Trends Endocrinol Metab* 2001; 12: 273-276.
- [67] Yaffe K. Estrogens, selective estrogen receptor modulators, and dementia: what is the evidence? *Ann N Y Acad Sci* 2001; 949: 215-222.
- [68] Henderson VW. Cognitive changes after menopause: influence of estrogen. *Clin Obstet Gynecol* 2008; 51: 618-626.
- [69] Tinkler GP, Tobin JR and Voytko ML. Effects of two years of estrogen loss or replacement on nucleus basalis cholinergic neurons and cholinergic fibers to the dorsolateral prefrontal and inferior parietal cortex of monkeys.
- [70] Matsuda Y, Hirano H and Watanabe Y. Effects of estrogen on acetylcholine release in frontal cortex of female rats: involvement of serotonergic neuronal systems.
- [71] Nakazawa K and Ohno Y. Modulation by estrogens and xenoestrogens of recombinant human neuronal nicotinic receptors.
- [72] Daniel JM and Dohanich GP. Acetylcholine mediates the estrogen-induced increase in NMDA receptor binding in CA1 of the hippocampus and the associated improvement in working memory.
- [73] Gibbs RB. Oestrogen and the cholinergic hypothesis: implications for oestrogen replacement therapy in postmenopausal women. [Review] [37 refs].
- [74] Gibbs RB, Hashash A and Johnson DA. Effects of estrogen on potassium-stimulated acetylcholine release in the hippocampus and overlying cortex of adult rats.
- [75] Simpkins JW, Singh M and Bishop J. The potential role for estrogen replacement therapy in the treatment of the cognitive decline and neurodegeneration associated with Alzheimer's disease. *Neurobiol Aging* 1994; 15 Suppl 2: S195-197.
- [76] Osterlund MK, Halldin C and Hurd YL. Effects of chronic 17beta-estradiol treatment on the serotonin 5-HT(1A) receptor mRNA and binding levels in the rat brain. *Synapse* 2000; 35: 39-44.
- [77] Mossner R, Schmitt A, Syagailo Y, Gerlach M, Riederer P and Lesch KP. The serotonin transporter in Alzheimer's and Parkinson's disease. *J Neural Transm Suppl* 2000; 345-350.
- [78] Cyr M, Landry M and Di Paolo T. Modulation by estrogen-receptor directed drugs of 5-hydroxytryptamine-2A receptors in rat brain. *Neuropsychopharmacology* 2000; 23(1): 69-78.
- [79] Sawada H and Shimohama S. Neuroprotective effects of estradiol in mesencephalic dopaminergic neurons. *Neurosci Biobehav Rev* 2000; 24: 143-147.
- [80] Sawada H, Ibi M, Kihara T, Urushitani M, Honda K, Nakanishi M, Akaike A and Shimohama S. Mechanisms of antiapoptotic effects of estrogens in nigral dopaminergic neurons. *FASEB J* 2000; 14: 1202-1214.
- [81] Sweet RA, Hamilton RL, Healy MT, Wisniewski SR, Hentleff R, Pollock BG, Lewis DA and DeKosky ST. Alterations of striatal dopamine receptor binding in Alzheimer disease are associated with Lewy body pathology and antemortem psychosis. *Arch Neurol* 2001; 58: 466-472.
- [82] Barbanti P, Fabbrini G, Ricci A, Bruno G, Cerbo R, Bronzetti E, Amenta F and Luigi Lenzi G. Reduced density of dopamine D2-like receptors on peripheral blood lymphocytes in Alzheimer's disease. *Mech Ageing Dev* 2000; 120: 65-75.
- [83] Kim YJ, Hur EM, Park TJ and Kim KT. Nongenomic inhibition of catecholamine secretion by 17beta-estradiol in PC12 cells. *J Neurochem* 2000; 74: 2490-2496.
- [84] Menozzi R, Cagnacci A, Zanni AL, Bondi M, Volpe A and Del Rio G. Sympathoadrenal response of postmenopausal women prior and during prolonged administration of estradiol. *Maturitas* 2000; 34: 275-281.
- [85] Komesaroff PA, Esler MD and Sudhir K. Estrogen supplementation attenuates glucocorticoid and catecholamine responses to mental stress in perimenopausal women. *J Clin Endocrinol Metab* 1999; 84: 606-610.
- [86] Dayas CV, Xu Y, Buller KM and Day TA. Effects of chronic oestrogen replacement on stress-induced activation of hypothalamic-pituitary-adrenal axis control pathways.
- [87] Struble RG, Cady C, Nathan BP and McAshey M. Apolipoprotein E may be a critical factor in hormone therapy neuroprotection. *Front Biosci* 2008; 13: 5387-5405.
- [88] Horsburgh K, McCarron MO, White F and Nicoll JA. The role of apolipoprotein E in Alzheimer's disease, acute brain injury and cerebrovascular disease: evidence of common mechanisms and utility of animal models. *Neurobiol Aging* 2000; 21: 245-255.
- [89] McCullough LD and Hurn PD. Estrogen and ischemic neuroprotection: an integrated view. *Trends Endocrinol Metab* 2003; 14: 228-235.
- [90] Li R, Shen Y, Yang LB, Lue LF, Finch C and Rogers J. Estrogen enhances uptake of amyloid beta-protein by microglia derived from the human cortex. *J Neurochem* 2000; 75: 1447-1454.
- [91] Xu H, Gouras GK, Greenfield JP, Vincent B, Naslund J, Mazzarelli L, Fried G, Jovanovic JN,

Estrogen and Alzheimer's disease

- Seeger M, Relkin NR, Liao F, Checler F, Buxbaum JD, Chait BT, Thinakaran G, Sisodia SS, Wang R, Greengard P and Gandy S. Estrogen reduces neuronal generation of Alzheimer beta-amyloid peptides. *Nat Med* 1998; 4: 447-451.
- [92] Tang M, Abplanalp W, Ayres S and Subbiah MT. Superior and distinct antioxidant effects of selected estrogen metabolites on lipid peroxidation. *Metabolism* 1996; 45: 411-414.
- [93] Paganini-Hill A. Estrogen replacement therapy and stroke. *Prog Cardiovasc Dis* 1995; 38: 223-242.
- [94] McAsey ME, Cady C, Jackson LM, Li M, Randall S, Nathan BP and Struble RG. Time course of response to estradiol replacement in ovariectomized mice: brain apolipoprotein E and synaptophysin transiently increase and glial fibrillary acidic protein is suppressed. *Exp Neurol* 2006; 197: 197-205.
- [95] Thomas T, Bryant M, Clark L, Garces A and Rhodin J. Estrogen and raloxifene activities on amyloid-beta-induced inflammatory reaction. *Microvascular Research*. 2001; 61: 28-39.
- [96] Lin MT and Beal MF. Mitochondrial dysfunction and oxidative stress in neurodegenerative diseases. *Nature* 2006; 443: 787-795.
- [97] Murphy AN, Fiskum G and Beal MF. Mitochondria in neurodegeneration: bioenergetic function in cell life and death. *J Cereb Blood Flow Metab* 1999; 19: 231-245.
- [98] Selkoe DJ. Alzheimer's disease: a central role for amyloid. *J Neuropathol Exp Neurol* 1994; 53: 438-447.
- [99] Yue X, Lu M, Lancaster T, Cao P, Honda S, Staufenbiel M, Harada N, Zhong Z, Shen Y and Li R. Brain estrogen deficiency accelerates Abeta plaque formation in an Alzheimer's disease animal model. *Proc Natl Acad Sci U S A* 2005; 102: 19198-19203.
- [100] Sundermann EE, Gilbert PE and Murphy C. The effect of hormone therapy on olfactory sensitivity is dependent on apolipoprotein E genotype. *Horm Behav* 2008; 54: 528-533.
- [101] Lambert JC, Coyle N and Lendon C. The allelic modulation of apolipoprotein E expression by oestrogen: potential relevance for Alzheimer's disease.
- [102] Rozovsky I, Hoving S, Anderson CP, O'Callaghan J and Finch CE. Equine estrogens induce apolipoprotein E and glial fibrillary acidic protein in mixed glial cultures.
- [103] Holtzman DM, Bales KR, Tenkova T, Fagan AM, Parsadanian M, Sartorius LJ, Mackey B, Olney J, McKeel D, Wozniak D and Paul SM. Apolipoprotein E isoform-dependent amyloid deposition and neuritic degeneration in a mouse model of Alzheimer's disease. *Proc Natl Acad Sci U S A* 2000; 97: 2892-2897.
- [104] Yaffe K, Haan M, Byers A, Tangen C and Kuller L. Estrogen use, APOE, and cognitive decline: evidence of gene-environment interaction. *Neurology* 2000; 54: 1949-1954.
- [105] Wang JM, Irwin RW and Brinton RD. Activation of estrogen receptor alpha increases and estrogen receptor beta decreases apolipoprotein E expression in hippocampus in vitro and in vivo. *Proc Natl Acad Sci U S A* 2006; 103: 16983-16988.
- [106] Kaplitt M, Gouras GK, Makimura H, Jovanovic J, Sweeney D, Greengard P, Relkin NR and Gandy S. Apolipoprotein E, A beta-amyloid, and the molecular pathology of Alzheimer's disease. Therapeutic implications. *Ann N Y Acad Sci* 1996; 802: 42-49.
- [107] Mahley RW, Weisgraber KH and Huang Y. Apolipoprotein E4: a causative factor and therapeutic target in neuropathology, including Alzheimer's disease. *Proc Natl Acad Sci U S A* 2006; 103: 5644-5651.
- [108] Geary GG, McNeill AM, Ospina JA, Krause DN, Korach KS and Duckles SP. Selected contribution: cerebrovascular nos and cyclooxygenase are unaffected by estrogen in mice lacking estrogen receptor-alpha. *J Appl Physiol* 2001; 91: 2391-2399; discussion 2389-2390.
- [109] Gingerich S and Krukoff TL. Estrogen modulates endothelial and neuronal nitric oxide synthase expression via an estrogen receptor beta-dependent mechanism in hypothalamic slice cultures. *Endocrinology* 2005; 146: 2933-2941.
- [110] Zhao L and Brinton RD. Estrogen receptor alpha and beta differentially regulate intracellular Ca(2+) dynamics leading to ERK phosphorylation and estrogen neuroprotection in hippocampal neurons. *Brain Res* 2007; 1172: 48-59.
- [111] Haynes MP, Sinha D, Russell KS, Collinge M, Fulton D, Morales-Ruiz M, Sessa WC and Bender JR. Membrane estrogen receptor engagement activates endothelial nitric oxide synthase via the PI3-kinase-Akt pathway in human endothelial cells. *Circ Res* 2000; 87: 677-682.
- [112] Simoncini T, Rabkin E and Liao JK. Molecular basis of cell membrane estrogen receptor interaction with phosphatidylinositol 3-kinase in endothelial cells. *Arterioscler Thromb Vasc Biol* 2003; 23: 198-203.
- [113] Stirone C, Boroujerdi A, Duckles SP and Krause DN. Estrogen receptor activation of phosphoinositide-3 kinase, akt, and nitric oxide signaling in cerebral blood vessels: rapid and long-term effects. *Mol Pharmacol* 2005; 67: 105-113.
- [114] Chen DB, Bird IM, Zheng J and Magness RR. Membrane estrogen receptor-dependent extracellular signal-regulated kinase pathway mediates acute activation of endothelial nitric oxide synthase by estrogen in uterine artery endothelial cells. *Endocrinology* 2004; 145: 113-125.
- [115] Salom JB, Burguete MC, Perez-Asensio FJ, Centeno JM, Torregrosa G and Alborch E. Acute

Estrogen and Alzheimer's disease

- relaxant effects of 17-beta-estradiol through non-genomic mechanisms in rabbit carotid artery. *Steroids* 2002; 67: 339-346.
- [116] Salom JB, Burguete MC, Perez-Asensio FJ, Torregrosa G and Alborch E. Relaxant effects of 17-beta-estradiol in cerebral arteries through Ca(2+) entry inhibition. *J Cereb Blood Flow Metab* 2001; 21: 422-429.
- [117] Tsang SY, Yao X, Chan HY, Chen ZY, Ming WC and Huang Y. Effect of 17beta-estradiol exposure on vasorelaxation induced by K(+) channel openers and Ca(2+) channel blockers. *Pharmacology* 2002; 65: 26-31.
- [118] Stirone C, Duckles SP and Krause DN. Multiple forms of estrogen receptor-alpha in cerebral blood vessels: regulation by estrogen. *Am J Physiol Endocrinol Metab* 2003; 284: E184-192.
- [119] Penotti M, Nencioni T, Gabrielli L, Farina M, Castiglioni E and Polvani F. Blood flow variations in internal carotid and middle cerebral arteries induced by postmenopausal hormone replacement therapy. *Am J Obstet Gynecol* 1993; 169: 1226-1232.
- [120] de Kleijn MJ, Wilimink HW, Bots ML, Bak AA, van der Schouw YT, Planellas J, Engelen S, Banga JD and Grobbee DE. Hormone replacement therapy and endothelial function. Results of a randomized controlled trial in healthy postmenopausal women. *Atherosclerosis* 2001; 159: 357-365.
- [121] Wakatsuki A, Okatani Y, Ikenoue N and Fukaya T. Effect of medroxyprogesterone acetate on endothelium-dependent vasodilation in postmenopausal women receiving estrogen. *Circulation* 2001; 104: 1773-1778.
- [122] Hashimoto M, Akishita M, Eto M, Ishikawa M, Kozaki K, Toba K, Sagara Y, Taketani Y, Orimo H and Ouchi Y. Modulation of endothelium-dependent flow-mediated dilatation of the brachial artery by sex and menstrual cycle. *Circulation* 1995; 92: 3431-3435.
- [123] Kawano H, Yasue H, Hirai N, Yoshida T, Fukushima H, Miyamoto S, Kojima S, Hokamaki J, Nakamura H, Yodoi J and Ogawa H. Effects of transdermal and oral estrogen supplementation on endothelial function, inflammation and cellular redox state. *Int J Clin Pharmacol Ther* 2003; 41: 346-353.
- [124] Kublickiene K, Svedas E, Landgren BM, Crisby M, Nahar N, Nisell H and Poston L. Small artery endothelial dysfunction in postmenopausal women: in vitro function, morphology, and modification by estrogen and selective estrogen receptor modulators. *J Clin Endocrinol Metab* 2005; 90: 6113-6122.
- [125] Chambliss KL and Shaul PW. Estrogen modulation of endothelial nitric oxide synthase. *Endocr Rev* 2002; 23: 665-686.
- [126] McNeill AM, Zhang C, Stanczyk FZ, Duckles SP and Krause DN. Estrogen increases endothelial nitric oxide synthase via estrogen receptors in rat cerebral blood vessels: effect preserved after concurrent treatment with medroxyprogesterone acetate or progesterone. *Stroke* 2002; 33: 1685-1691.
- [127] Pelligrino DA, Ye S, Tan F, Santizo RA, Feinstein DL and Wang Q. Nitric-oxide-dependent pial arteriolar dilation in the female rat: effects of chronic estrogen depletion and repletion. *Biochem Biophys Res Commun* 2000; 269: 165-171.
- [128] Skarsgard P, van Breemen C and Laher I. Estrogen regulates myogenic tone in pressurized cerebral arteries by enhanced basal release of nitric oxide. *Am J Physiol* 1997; 273: H2248-2256.
- [129] Sobey CG, Weiler JM, Boujaoude M and Woodman OL. Effect of short-term phytoestrogen treatment in male rats on nitric oxide-mediated responses of carotid and cerebral arteries: comparison with 17beta-estradiol. *J Pharmacol Exp Ther* 2004; 310: 135-140.
- [130] Stirone C, Chu Y, Sunday L, Duckles SP and Krause DN. 17 Beta-estradiol increases endothelial nitric oxide synthase mRNA copy number in cerebral blood vessels: quantification by real-time polymerase chain reaction. *Eur J Pharmacol* 2003; 478: 35-38.
- [131] Geary GG, Krause DN and Duckles SP. Estrogen reduces myogenic tone through a nitric oxide-dependent mechanism in rat cerebral arteries. *Am J Physiol* 1998; 275: H292-300.
- [132] Geary GG, Krause DN and Duckles SP. Gonadal hormones affect diameter of male rat cerebral arteries through endothelium-dependent mechanisms. *Am J Physiol Heart Circ Physiol* 2000; 279: H610-618.
- [133] Geary GG, Krause DN and Duckles SP. Estrogen reduces mouse cerebral artery tone through endothelial NOS- and cyclooxygenase-dependent mechanisms. *Am J Physiol Heart Circ Physiol* 2000; 279: H511-519.
- [134] Grohe C, Kann S, Fink L, Djoufack PC, Paehr M, van Eickels M, Vetter H, Meyer R and Fink KB. 17 Beta-estradiol regulates nNOS and eNOS activity in the hippocampus. *Neuroreport* 2004; 15: 89-93.
- [135] Pelligrino DA, Santizo R, Baughman VL and Wang Q. Cerebral vasodilating capacity during forebrain ischemia: effects of chronic estrogen depletion and repletion and the role of neuronal nitric oxide synthase. *Neuroreport* 1998; 9: 3285-3291.
- [136] Ospina JA, Duckles SP and Krause DN. 17beta-estradiol decreases vascular tone in cerebral arteries by shifting COX-dependent vasoconstriction to vasodilation. *Am J Physiol Heart Circ Physiol* 2003; 285: H241-250.
- [137] Ospina JA, Krause DN and Duckles SP. 17beta-estradiol increases rat cerebrovascular prostacyclin synthesis by elevating

Estrogen and Alzheimer's disease

- cyclooxygenase-1 and prostacyclin synthase. *Stroke* 2002; 33: 600-605.
- [138] Li X, Geary GG, Gonzales RJ, Krause DN and Duckles SP. Effect of estrogen on cerebrovascular prostaglandins is amplified in mice with dysfunctional NOS. *Am J Physiol Heart Circ Physiol* 2004; 287: H588-594.
- [139] Chrissobolis S, Budzyn K, Marley PD and Sobey CG. Evidence that estrogen suppresses rho-kinase function in the cerebral circulation in vivo. *Stroke* 2004; 35: 2200-2205.
- [140] Shay J, Futo J, Badrov N and Moss J. Estrogen withdrawal selectively increases serotonin reactivity in rabbit basilar artery. *Life Sci* 1994; 55: 1071-1081.
- [141] Zhang F, Ram JL, Standley PR and Sowers JR. 17 beta-Estradiol attenuates voltage-dependent Ca²⁺ currents in A7r5 vascular smooth muscle cell line. *Am J Physiol* 1994; 266: C975-980.
- [142] Chen JQ, Eshete M, Alworth WL and Yager JD. Binding of MCF-7 cell mitochondrial proteins and recombinant human estrogen receptors alpha and beta to human mitochondrial DNA estrogen response elements. *J Cell Biochem* 2004; 93: 358-373.
- [143] Stirone C, Duckles SP, Krause DN and Procaccio V. Estrogen increases mitochondrial efficiency and reduces oxidative stress in cerebral blood vessels. *Mol Pharmacol* 2005; 68: 959-965.
- [144] Nilsen J, Chen S, Irwin RW, Iwamoto S and Brinton RD. Estrogen protects neuronal cells from amyloid beta-induced apoptosis via regulation of mitochondrial proteins and function. *BMC Neurosci* 2006; 7: 74.
- [145] Nilsen J and Brinton RD. Mitochondria as therapeutic targets of estrogen action in the central nervous system. *Curr Drug Targets CNS Neurol Disord* 2004; 3: 297-313.
- [146] Ono H, Sasaki Y, Bamba E, Seki J, Giddings JC and Yamamoto J. Cerebral thrombosis and microcirculation of the rat during the oestrous cycle and after ovariectomy. *Clin Exp Pharmacol Physiol* 2002; 29: 73-78.
- [147] Ospina JA, Brevig HN, Krause DN and Duckles SP. Estrogen suppresses IL-1beta-mediated induction of COX-2 pathway in rat cerebral blood vessels. *Am J Physiol Heart Circ Physiol* 2004; 286: H2010-2019.
- [148] Sunday L, Tran MM, Krause DN and Duckles SP. Estrogen and progestagens differentially modulate vascular proinflammatory factors. *Am J Physiol Endocrinol Metab* 2006; 291: E261-267.
- [149] Sunday L, Osuna C, Krause DN and Duckles SP. Age alters cerebrovascular inflammation and effects of estrogen. *Am J Physiol Heart Circ Physiol* 2007; 292: H2333-2340.
- [150] Johnson AB, Bake S, Lewis DK and Sohrabji F. Temporal expression of IL-1beta protein and mRNA in the brain after systemic LPS injection is affected by age and estrogen. *J Neuroimmunol* 2006; 174: 82-91.
- [151] Chambliss KL and Shaul PW. Rapid activation of endothelial NO synthase by estrogen: evidence for a steroid receptor fast-action complex (SRFC) in caveolae. *Steroids* 2002; 67: 413-419.
- [152] Chambliss KL, Yuhanna IS, Anderson RG, Mendelsohn ME and Shaul PW. ERbeta has nongenomic action in caveolae. *Mol Endocrinol* 2002; 16: 938-946.
- [153] Haynes MP, Li L, Russell KS and Bender JR. Rapid vascular cell responses to estrogen and membrane receptors. *Vascul Pharmacol* 2002; 38: 99-108.
- [154] Levin ER. Cellular functions of plasma membrane estrogen receptors. *Steroids* 2002; 67: 471-475.
- [155] Chambliss KL, Simon L, Yuhanna IS, Mineo C and Shaul PW. Dissecting the basis of nongenomic activation of endothelial nitric oxide synthase by estradiol: role of ERalpha domains with known nuclear functions. *Mol Endocrinol* 2005; 19: 277-289.
- [156] Pietras RJ, Levin ER and Szego CM. Estrogen receptors and cell signaling. *Science* 2005; 310: 51-53; author reply 51-53.
- [157] Ho KJ and Liao JK. Nonnuclear actions of estrogen. *Arterioscler Thromb Vasc Biol* 2002; 22: 1952-1961.
- [158] Florian M, Lu Y, Angle M and Magder S. Estrogen induced changes in Akt-dependent activation of endothelial nitric oxide synthase and vasodilation. *Steroids* 2004; 69: 637-645.
- [159] Momoi H, Ikomi F and Ohhashi T. Estrogen-induced augmentation of endothelium-dependent nitric oxide-mediated vasodilation in isolated rat cerebral small arteries. *Jpn J Physiol* 2003; 53: 193-203.
- [160] Watanabe Y, Littleton-Kearney MT, Traystman RJ and Hurn PD. Estrogen restores postischemic pial microvascular dilation. *Am J Physiol Heart Circ Physiol* 2001; 281: H155-160.
- [161] Hu L, Yue Y, Zuo PP, Jin ZY, Feng F, You H, Li ML and Ge QS. Evaluation of neuroprotective effects of long-term low dose hormone replacement therapy on postmenopausal women brain hippocampus using magnetic resonance scanner. *Chin Med Sci J* 2006; 21: 214-218.
- [162] Yue Y, Hu L, Tian QJ, Jiang JM, Dong YL, Jin ZY, Cheng YH, Hong X, Ge QS and Zuo PP. Effects of long-term, low-dose sex hormone replacement therapy on hippocampus and cognition of postmenopausal women of different apoE genotypes. *Acta Pharmacol Sin* 2007; 28: 1129-1135.
- [163] McEwen B. Estrogen actions throughout the brain. *Recent Prog Horm Res* 2002; 57: 357-384.
- [164] Gresack JE and Frick KM. Effects of

Estrogen and Alzheimer's disease

- continuous and intermittent estrogen treatments on memory in aging female mice. *Brain Res* 2006; 1115: 135-147.
- [165] Rissanen A, Puolivali J, van Groen T and Riekkinen P, Jr. In mice tonic estrogen replacement therapy improves non-spatial and spatial memory in a water maze task. *Neuroreport* 1999; 10: 1369-1372.
- [166] Gresack JE and Frick KM. Post-training estrogen enhances spatial and object memory consolidation in female mice. *Pharmacol Biochem Behav* 2006; 84: 112-119.
- [167] Liu XA, Zhu LQ, Zhang Q, Shi HR, Wang SH, Wang Q and Wang JZ. Estradiol attenuates tau hyperphosphorylation induced by upregulation of protein kinase-A. *Neurochem Res* 2008; 33: 1811-1820.
- [168] Asthana S, Baker L, Craft S, Lofgreen C, Avery E, Raskind M, Cherrier M, Wong M, Veith R and Plymate S. Estrogen-induced enhancement in memory in postmenopausal women with Alzheimer's disease. *Neurobiol Aging* 1998; 19(4S): Abstract # 748, page S178.
- [169] Honjo H, Ogino Y, Tanaka K, Urabe M, Kashiwagi T, Ishihara S, Okada H, Araki K, Fushiki S, Nakajima K, Hayashi K, Hayashi M and Sakaki T. An effect of conjugated estrogen to cognitive impairment in women with senile dementia-Alzheimer's type: A placebo-controlled, double-blind study. *J Jpn Menopause Soc* 1993; 1: 167-171.
- [170] Brookmeyer R, Gray S and Kawas C. Projections of Alzheimer's disease in the United States and the public health impact of delaying disease onset. *Am J Public Health* 1998; 88: 1337-1342.
- [171] Morrison JH, Brinton RD, Schmidt PJ and Gore AC. Estrogen, menopause, and the aging brain: how basic neuroscience can inform hormone therapy in women. *J Neurosci* 2006; 26: 10332-10348.